Surgery before radiation therapy for neuroendocrine tumors
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests if removing as much tumor as possible through surgery before a targeted radiation therapy (PRRT) can help people with well-differentiated neuroendocrine tumors that have spread to the liver. The goal is to see if this approach works better than radiation therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a type of neuroendocrine tumor that is considered low or intermediate grade (not aggressive).
- The tumor shows up on a special PET scan (copper-64 dotatate) done in the last 6 months.
- You have at least one tumor in the liver.
- Your kidney, liver, and blood cell levels are within acceptable ranges.
- You are willing to use effective birth control if you are of childbearing age or able to father children.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether giving chemotherapy after surgery can lower cancer recurrence risk in people with high-risk pancreatic neuroendocrine tumors (NETs). It may help you by testing an added treatment after the tumor has been removed.
This trial combines external radiation with a targeted radioactive drug (PRRT) to treat large, slow-growing neuroendocrine tumors in the gut that have spread and are not removable by surgery. It aims to see if this combination works better than either treatment alone.
This trial tests whether repeating a targeted radioactive treatment (177Lu-DOTATATE) works better than standard options in people with metastatic gastroenteropancreatic neuroendocrine tumors. It may help by controlling tumor growth after the first round of this therapy stops working.
This Phase 3 study tests whether a targeted radiation treatment approach (using a special “PRRT” scan-guided method) works better to control advanced neuroendocrine tumors. It’s designed for tumors that show strong targeting on a specific PET scan and that are growing despite prior treatment (with some limits).
This trial tests whether adding chemotherapy to a standard treatment (PRRT) works better than PRRT alone for people with certain types of digestive tract or pancreatic neuroendocrine tumors. It is for those whose tumors have higher activity on scans or are growing.
This trial tests a treatment called PRRT, which delivers a radioactive medicine directly to tumor cells, for advanced neuroendocrine tumors. It may help those whose tumors are growing despite octreotide treatment, especially when scans show tumor uptake of specific tracers.
Hear when a new Metastatic Malignant Neoplasm in the Liver trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.